Insulin secretion: difference between revisions
Diff·revision 15 → 16·12:29, 25 Apr 2025
Difference between revision 15 and revision 16 of Insulin secretion. 4 lines changed; the page grew by 527 bytes.
| Revision 15 — 17:16, 6 Apr 2025 ProglucagonPia (talk) alphabetise the see-also list 5,442 bytes ±0 | Revision 16 — 12:29, 25 Apr 2025 SerialCommaSeb (talk) British spelling per PP:MOS 5,969 bytes +527 | ||
|---|---|---|---|
| 34 | Secretion is measured indirectly. Peripheral insulin concentration understates secretion because of first-pass hepatic extraction, so [[C-peptide]] — co-secreted equimolar with insulin and not extracted by the liver — is the preferred analyte for quantifying secretory rate. Deconvolution of C-peptide kinetics gives a secretion profile; simpler indices such as HOMA-B and the insulinogenic index are cruder but require only a fasting or a two-point sample. | 34 | Secretion is measured indirectly. Peripheral insulin concentration understates secretion because of first-pass hepatic extraction, so [[C-peptide]] — co-secreted equimolar with insulin and not extracted by the liver — is the preferred analyte for quantifying secretory rate. Deconvolution of C-peptide kinetics gives a secretion profile; simpler indices such as HOMA-B and the insulinogenic index are cruder but require only a fasting or a two-point sample. |
| 35 | 35 | ||
| + | 36 | Anyone comparing published secretion data should check which measure was used. Fasting insulin, HOMA-B, C-peptide deconvolution and clamp-derived first-phase measurements are not interchangeable, and a difference between studies is as likely to be methodological as physiological.{{r|bergman2002}} | |
| + | 37 | ||
| 36 | == References == | 38 | == References == |
| 37 | {{reflist}} | 39 | {{reflist}} |
| ⋮ | ⋮ | ||
| 39 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | 41 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> |
| 40 | <ref name="campbell2013">Campbell JE, Drucker DJ. "Pharmacology, physiology, and mechanisms of incretin hormone action." ''Cell Metabolism'' 17(6):819–837 (2013). PMID 23684623.</ref> | 42 | <ref name="campbell2013">Campbell JE, Drucker DJ. "Pharmacology, physiology, and mechanisms of incretin hormone action." ''Cell Metabolism'' 17(6):819–837 (2013). PMID 23684623.</ref> |
| + | 43 | <ref name="bergman2002">Bergman RN, Ader M, Huecking K, Van Citters G. "Accurate assessment of beta-cell function: the hyperbolic correction." ''Diabetes'' 51 Suppl 1:S212–S220 (2002). PMID 11815482.</ref> | |
| 41 | 44 | ||
| 42 | == See also == | 45 | == See also == |
| ⋮ | ⋮ | ||
| 45 | * [[Incretin effect]] | 48 | * [[Incretin effect]] |
| 46 | * [[C-peptide]] | 49 | * [[C-peptide]] |
| + | 50 | * [[Hypoglycaemia]] | |
| 47 | 51 | ||
| 48 | {{DEFAULTSORT:Insulin secretion}} | 52 | {{DEFAULTSORT:Insulin secretion}} |